Healthcare Triangle Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
HCTI$4.21-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2024 | 2023 | |
| (In thousands) | ||
| Cash flows from operating activities | ||
| Net income (loss) | $(4,621) | $(7,007) |
| Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities | ||
| Change in fair value of warrants | 379 | - |
| Depreciation and amortization | 1,034 | 2,388 |
| Common stock issued for services | 22 | 51 |
| Stock compensation expenses | 106 | 197 |
| Amortization of debt discount | 217 | 75 |
| Changes in operating assets and liabilities: | ||
| (Increase)/ decrease in: | ||
| Accounts receivable | 1,626 | 1,396 |
| Other current assets | 678 | 194 |
| Due from related party | 304 | 1,060 |
| Increase/ (decrease) in: | ||
| Accounts payable and accrued expenses | 345 | (321) |
| Other current liabilities | (360) | (783) |
| Net cash provided by/ (used in) operating activities | (270) | (2,750) |
| Cash flows from investing activities | ||
| (Purchase)/sale of property and equipment | — | (7) |
| Net cash provided by/ (used in) investing activities | — | (7) |
| Cash flows from financing activities | ||
| Increase in additional paid-up capital | 956 | 499 |
| Increase/(decrease) in short term borrowing | (1,892) | 992 |
| Repurchases of common stock | - | — |
| Net cash provided by/ (used in) financing activities | (936) | 1,491 |
| Net increase (decrease) in cash and cash equivalents | (1,206) | (1,266) |
| Cash and cash equivalents | ||
| Cash and cash equivalents at the beginning of the period | $1,234 | $1,341 |
| Cash and cash equivalents at the end of the period | $28 | $75 |
| Supplementary disclosure of cash flows information | ||
| Interest | 360 | 663 |
| Income taxes | 8 | 28 |
| Non-cash investing and financing activities | ||
| Non-Cash Conversion of debt into common stock | $1,181 | — |
| Reclassification of contingent consideration to derivative liability | — | $740 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.